PE20131046A1 - Derivados aminolactama como agentes anti-inflamatorios - Google Patents

Derivados aminolactama como agentes anti-inflamatorios

Info

Publication number
PE20131046A1
PE20131046A1 PE2012002286A PE2012002286A PE20131046A1 PE 20131046 A1 PE20131046 A1 PE 20131046A1 PE 2012002286 A PE2012002286 A PE 2012002286A PE 2012002286 A PE2012002286 A PE 2012002286A PE 20131046 A1 PE20131046 A1 PE 20131046A1
Authority
PE
Peru
Prior art keywords
inflammatory agents
ona
aminolactam
tetrahydropyridin
integer
Prior art date
Application number
PE2012002286A
Other languages
English (en)
Inventor
David John Grainger
David John Fox
Original Assignee
Boehringer Ingelheim Int
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Cambridge Entpr Ltd filed Critical Boehringer Ingelheim Int
Publication of PE20131046A1 publication Critical patent/PE20131046A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE 3-AMINOLACTAMA DE FORMULA (I), DONDE n ES UN ENTERO DE 1 A 4; k ES UN ENTERO DE 1 A 5; X ES UN GRUPO ALQUILO, HALOALQUILO, HIDROXIALQUILO, ENTRE OTROS. SON COMPUESTOS FAVORITOS: (S)-3-(4'-ETILBENZOILAMINO)-AZEPAN-2-ONA, (S)-3-(4'-OCTILBENZOILAMINO)-TETRAHIDROPIRIDIN-2-ONA, (S)-3-(4'-HEXILBENZOILAMINO)-TETRAHIDROPIRIDIN-2-ONA, ENTRE OTROS. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA DE QUIMIOQUINAS Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADESINFLAMATORIAS
PE2012002286A 2010-06-08 2011-06-08 Derivados aminolactama como agentes anti-inflamatorios PE20131046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1009603.0A GB201009603D0 (en) 2010-06-08 2010-06-08 Anti-inflammatory agent

Publications (1)

Publication Number Publication Date
PE20131046A1 true PE20131046A1 (es) 2013-09-23

Family

ID=42471347

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012002288A PE20130772A1 (es) 2010-06-08 2011-06-08 Derivados de sulfonamida de 3-aminolactamas como agentes anti-inflamatorios
PE2012002286A PE20131046A1 (es) 2010-06-08 2011-06-08 Derivados aminolactama como agentes anti-inflamatorios

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012002288A PE20130772A1 (es) 2010-06-08 2011-06-08 Derivados de sulfonamida de 3-aminolactamas como agentes anti-inflamatorios

Country Status (21)

Country Link
US (2) US20130172318A1 (es)
EP (2) EP2580196A1 (es)
JP (2) JP2013531647A (es)
KR (2) KR20130086952A (es)
CN (2) CN103119021A (es)
AP (2) AP2012006559A0 (es)
AU (1) AU2011263531A1 (es)
BR (2) BR112012030816A2 (es)
CA (2) CA2798213A1 (es)
CL (1) CL2012003460A1 (es)
CO (2) CO6670553A2 (es)
GB (1) GB201009603D0 (es)
IL (2) IL222798A0 (es)
MA (2) MA34370B1 (es)
MX (2) MX2012014290A (es)
PE (2) PE20130772A1 (es)
PH (2) PH12012502167A1 (es)
SG (2) SG185129A1 (es)
TN (2) TN2012000521A1 (es)
WO (2) WO2011154695A1 (es)
ZA (2) ZA201208367B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ［５，４―ｂ］アゼピン誘導体
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
IT1247698B (it) 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
JP3206042B2 (ja) 1991-10-31 2001-09-04 ミノルタ株式会社 新規トリアミノ化合物を用いた電荷輸送材料、このトリアミノ化合物を含有する感光体およびエレクトロルミネセンス素子
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
CA2363067C (en) 1999-01-12 2012-03-20 David J. Grainger Compounds and methods to inhibit or augment an inflammatory response
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2004084898A1 (en) * 2003-03-24 2004-10-07 Actimis Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
CA2544350A1 (en) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
CA2547651C (en) 2003-12-01 2015-06-23 Cambridge University Technical Services Limited Anti-inflammatory agents
AU2005261932B2 (en) * 2004-07-13 2011-10-13 F. Hoffmann-La Roche Ag Sulfonamide derivatives
GB2418425B (en) * 2004-08-11 2008-09-03 Univ Cambridge Tech Anti-inflammatory agents
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2423085C (en) 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
EP1896036B1 (en) * 2005-06-15 2013-01-23 Cambridge Enterprise Limited Anti-inflammatory agents
GB0512238D0 (en) 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
EP1915345B1 (en) 2005-08-12 2010-12-22 F. Hoffmann-La Roche AG Fluoro substituted 2-oxo azepan derivatives
JP5335426B2 (ja) 2005-09-27 2013-11-06 アイアールエム・リミテッド・ライアビリティ・カンパニー ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
CA2694454A1 (en) 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Chemokine analogs
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions

Also Published As

Publication number Publication date
KR20130115082A (ko) 2013-10-21
PH12012502169A1 (en) 2013-01-07
GB201009603D0 (en) 2010-07-21
EP2580196A1 (en) 2013-04-17
TN2012000521A1 (en) 2014-04-01
CL2012003460A1 (es) 2013-08-16
US20130172318A1 (en) 2013-07-04
JP2013531647A (ja) 2013-08-08
KR20130086952A (ko) 2013-08-05
MX2012014290A (es) 2013-05-01
AU2011263531A1 (en) 2012-11-22
IL222866A0 (en) 2012-12-31
BR112012030816A2 (pt) 2016-11-01
WO2011154696A1 (en) 2011-12-15
SG185129A1 (en) 2012-12-28
EP2580197A1 (en) 2013-04-17
AP2012006559A0 (en) 2012-12-31
CN103119021A (zh) 2013-05-22
PE20130772A1 (es) 2013-07-03
MX2012014291A (es) 2013-05-01
CA2798129A1 (en) 2011-12-15
CN103080090A (zh) 2013-05-01
CO6670569A2 (es) 2013-05-15
JP2013528201A (ja) 2013-07-08
ZA201208367B (en) 2013-10-30
BR112012031136A2 (pt) 2017-08-08
SG185130A1 (en) 2012-12-28
AP2012006560A0 (en) 2012-12-31
IL222798A0 (en) 2012-12-31
US20130203734A1 (en) 2013-08-08
PH12012502167A1 (en) 2013-01-07
MA34370B1 (fr) 2013-07-03
CO6670553A2 (es) 2013-05-15
MA34369B1 (fr) 2013-07-03
CA2798213A1 (en) 2011-12-15
ZA201208406B (en) 2013-07-31
WO2011154695A1 (en) 2011-12-15
TN2012000525A1 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
EA201390198A1 (ru) Гетероциклическое соединение
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
MX336381B (es) Boronatos como inhibidores de arginasa.
EA201290460A1 (ru) Производные азола, способы их получения, промежуточные продукты, средства для сельского хозяйства и садоводства
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MA32811B1 (fr) Nouveaux composés
MA33939B1 (fr) 5-alcynyl-pyrimidines
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
IN2012DN01350A (es)
NZ723198A (en) Anthelmintic compounds and compositions and methods of using thereof
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
UA112061C2 (uk) Активуючі ampk гетероциклічні сполуки і способи їх використання
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
CO6190517A2 (es) Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f]indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
EA201391720A1 (ru) Замещенные диоксопиперидинилфталимидные производные
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.
MX2012002641A (es) Inhibidores de cinasa janus (jak).

Legal Events

Date Code Title Description
FD Application declared void or lapsed